Bridging Analyses: The Role of Cost Per Event A...

By João L. Carapinha

March 17, 2026

This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucag...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...